Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss

Next Previous
X
Search
Trial Profile

A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FX 322 (Primary)
  • Indications Noise-induced hearing loss; Sensorineural hearing loss; Sudden hearing loss
  • Focus Therapeutic Use
  • Sponsors Frequency Therapeutics

    • Most Recent Events

    • 13 Mar 2023 According to a Frequency Therapeutics media release, company announced given the outcome of this study, the Company has undertaken actions to reduce expenses and headcount, these cuts will be completed by the end of April 2023.
    • 10 Mar 2023 Status changed to discontinued, according to a Frequency therapeutic media release.
    • 13 Feb 2023 Primary endpoint (Speech Perception) has not been met, according to a Frequency Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top